U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H42N2O2S2
Molecular Weight 454.732
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of ALBITIAZOLIUM

SMILES

CC1=C(CCO)SC=[N+]1CCCCCCCCCCCC[N+]2=CSC(CCO)=C2C

InChI

InChIKey=UZPXHZIQHWKNPF-UHFFFAOYSA-N
InChI=1S/C24H42N2O2S2/c1-21-23(13-17-27)29-19-25(21)15-11-9-7-5-3-4-6-8-10-12-16-26-20-30-24(14-18-28)22(26)2/h19-20,27-28H,3-18H2,1-2H3/q+2

HIDE SMILES / InChI

Molecular Formula C24H40N2O2S2
Molecular Weight 452.717
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Albitiazolium (SAR97276) is a clinical antimalarial candidate from a series of choline analogs designed to inhibit plasmodial phospholipid metabolism. Albitiazolium exerts powerful in vitro and in vivo antimalarial activities. Albitiazolium has been shown to have appropriate pharmacokinetic and safety parameters in humans and it was being tested in phase II clinical trials by Sanofi, with confirmed antimalarial activity in adult patients. However, Sanofi discontinued development of Albitiazolium.

Approval Year

PubMed

PubMed

TitleDatePubMed
A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.
2014

Sample Use Guides

A total of 113 malaria patients received SAR97276. Adults were randomized to receive a single dose SAR97296 given either intramuscularly (IM) (0.18 mg/kg) or intravenously (IV) (0.14 mg/kg). If a single dose was not efficacious a second adult group was planned to test a three dose regimen administered IM once daily for 3 days. Single dose SAR97276 showed insufficient efficacy in adults (IM: 20 of 34 cured, 59%; and IV: 23/30 cured, 77%). The 3-day IM regimen showed acceptable efficacy in adults (27/30, 90%) but not in children (13/19, 68%).
Route of Administration: Parenteral
Albitiazolium strongly inhibited in vitro plasmodial growth with an IC50 value of 4.2 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:15:32 GMT 2023
Edited
by admin
on Fri Dec 15 17:15:32 GMT 2023
Record UNII
HKM715W3UT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALBITIAZOLIUM
Common Name English
ALBITIAZOLIUM CATION
Common Name English
SAR97276
Code English
ALBITIAZOLIUM ION
Common Name English
SAR-97276
Code English
3,3'-(DODECAN-1,12-DIYL)BIS(5-(2-HYDROXYETHYL)-4-METHYL-1,3-THIAZOL-3-IUM)
Systematic Name English
Code System Code Type Description
PUBCHEM
11377023
Created by admin on Fri Dec 15 17:15:32 GMT 2023 , Edited by admin on Fri Dec 15 17:15:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID10226315
Created by admin on Fri Dec 15 17:15:32 GMT 2023 , Edited by admin on Fri Dec 15 17:15:32 GMT 2023
PRIMARY
SMS_ID
300000042526
Created by admin on Fri Dec 15 17:15:32 GMT 2023 , Edited by admin on Fri Dec 15 17:15:32 GMT 2023
PRIMARY
FDA UNII
HKM715W3UT
Created by admin on Fri Dec 15 17:15:32 GMT 2023 , Edited by admin on Fri Dec 15 17:15:32 GMT 2023
PRIMARY
CAS
753439-46-2
Created by admin on Fri Dec 15 17:15:32 GMT 2023 , Edited by admin on Fri Dec 15 17:15:32 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY